Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

$(1.17) $0.25

Diluted $(1.17) (i) $0.24 (k)

Weighted average common shares -

basic 46,671 46,671

Weighted average common shares -

diluted 46,671 (i) 48,512 (k)

(a) In calculating net income or loss on an adjusted cash basis, the

Company excludes from net income or loss (i) certain non-cash charges,

including amortization expense and stock-based compensation expense, (ii)

non-recurring charges and income, and (iii) certain other charges and

income that have a significant positive or negative impact on results yet

do not occur on a consistent or regular basis in its business. In

determining whether a particular item meets one of these criteria,

management considers facts and circumstances that it believes are

relevant. Management believes that excluding such charges and income from

income or loss allows investors and management to evaluate and compare the

Company's operating results from continuing operations from period to

period in a meaningful and consistent manner. Due to the frequency of

their occurrence in its business, the Company does not adjust net income

or loss for the costs associated with litigation, including payments made

or received through settlements. It should be noted that "net income or

loss on an adjusted cash basis" is not a standard financial measurement

under accounting principles generally accepted in the United States of

America ("GAAP") and should not be considered as an alternative to net

income or loss or cash flow from operating activities, as a measure of

liquidity or as an indicator of operating performance or any measure of

performance derived in accordance with GAAP.

(b) Amortizati
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... August 26, 2015 Israel Proves Its Place ... 1 st place  Wayerz comes in 5 th ... Israel by venture capital fund JVP, with Chinese consulting ... China , Israel , ... Impressive achievement for the Israeli representatives in the final ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... Deliver Electronic X-ray-Based, Therapy Directly to ... SUNNYVALE, Calif., March 17 Xoft, ... clearance from the U.S. Food & Drug,Administration ... a,proprietary technology platform designed to deliver localized,non-radioactive, ...
... poised to ... MENLO PARK, Calif., March 17 Apieron, Inc., ... has received,clearance to market by the U.S. Food and ... nitric oxide (eNO), which is a,well-established indicator of airway ...
... -, SAN DIEGO, Calif., March 17 BioMed ... its board of directors has,declared a first quarter 2008 ... increase over the company,s previous quarterly dividend of $0.31,per ... dividend,of $1.34 per common share., BioMed also announced ...
Cached Biology Technology:FDA Clears Expanded Use of Xoft's Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 2Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management 3BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend 2
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... The Human Microbiome Project has awarded more than $42 million to ... live in or on our bodies affect our health, the National ... microbiome is all the microorganisms that reside in or on the ... in 2007 as part of the NIH Common Fund,s Roadmap for ...
... 2009 Chronix Biomedical today reported that a new ... diagnostic and prognostic utility of using circulating fragments of ... fragments, referred to as serum DNA, are released into ... process. Chronix Biomedical has developed proprietary technology that can ...
... , -- Results from Parascript SignatureXpert confirm that signatures ... Court of Moscow to initiate forensic examination and expert ... , BOULDER, Colo., June 22 Parascript, ... today announced that it has partnered with the Moscow ...
Cached Biology News:NIH expands Human Microbiome Project; funds sequencing centers and disease projects 2NIH expands Human Microbiome Project; funds sequencing centers and disease projects 3NIH expands Human Microbiome Project; funds sequencing centers and disease projects 4NIH expands Human Microbiome Project; funds sequencing centers and disease projects 5Study shows Chronix technology using serum DNA can identify early presence of disease 2Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case 2Parascript Signature Verification Technology Used by Moscow Law Firm to Detect Signature Fraud in $160,000 Debt Collection Case 3
Liquid. PBS containing 10 mM NaN 3 . AVOID FREEZE/THAW CYCLES. Recognizes α1, 2, 3, 5, 6 and 7 subunits of 20S proteasome. ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Goat polyclonal to Lipocalin 2...
Biology Products: